Clinical, Epidemiological and Therapeutic Evaluation in 14 Cases of Inflammatory Breast Cancer in Canines

• Main Authors: Celina Gomes da Silva, Rafael Ricardo Huppes, Andrigo Barboza de Nardi, Ricardo Andres Ramirez Uscategui, Renato Linhares Sampaio, Fernando Wiecheteck de Souza, Joice Lara Maia Faria
• Format: Article
• Language: English
• Published: Universidad de La Salle 2014-06-01
• Series: Revista de Medicina Veterinaria
• Subjects: carboplatino; ciclofosfamida; doxorrubicina; inhibidores de la ciclooxigenasa- 2; quimioterapia
• Online Access: http://revistas.lasalle.edu.co/index.php/mv/article/view/3026
• ISSN: 0122-9354; 2389-8526

With the aim of evaluating clinical aspects, age, breed, presence of metastasis, chemotherapeutical protocol, use of COX-2 inhibitors and survival rate in female dogs diagnosed with inflammatory carcinoma at the Hospital Veterinario de Uberaba (HVU), a retrospective analysis was performed on the medical records of 14 female dogs seen at HVU between July, 2011 and July, 2012 and diagnosed with inflammatory breast cancer. The breeds included were crossbred, poodle, Brazilian terrier, teckel and Belgian shepherd. Average age: 11.1 years. Outbreaks of distant metastasis were detected in 7 animals, out of which 5 patients received COX-2 inhibitors as sole treatment and only 4 received chemotherapeutical treatment. The protocol, constituted by piroxicam, cyclophosphamide, carboplatin and doxorubicin showed the highest survival time (210 days). In conclusion, inflammatory carcinoma is a disease of bad prognosis, short survival time and produces systemic alterations that reduce therapeutic response. Apparently, the most accurate therapeutic form is the association of COX-2 inhibitors and chemotherapeutics; however, controlled clinical studies are needed in order to evaluate these suggestions.